Two questions dominate how a peptide Certificate of Analysis gets read: how pure is it, and is it the right molecule. HPLC purity answers the first. Mass spectrometry identity confirmation answers the second, by matching an observed mass against the theoretical mass of the intended peptide. That second check has a known limit, one flagged in our own coverage of it: mass alone cannot distinguish leucine from isoleucine, because the two amino acids are isobaric, identical in mass. Peptide mapping is the technique built to close exactly that kind of gap, and it does it by refusing to trust the intact molecule's mass as the whole story.
What peptide mapping actually is
The definition comes from the same regulatory literature that governs biotechnology-derived drug substances. ICH Q6B, Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, describes a peptide map this way: "Selective fragmentation of the product into discrete peptides is performed using suitable enzymes or chemicals and the resulting peptide fragments are analyzed by HPLC or other appropriate analytical procedure. The peptide fragments should be identified to the extent possible using techniques such as amino acid compositional analysis, N-terminal sequencing, or mass spectrometry." The guideline goes on to note that peptide mapping "using an appropriately validated procedure is a method that is frequently used to confirm desired product structure for lot release purposes."
Unpacked, that is a three-step process. First, cut the peptide into smaller, defined pieces, using an enzyme (trypsin is the standard choice for larger proteins, cleaving after lysine and arginine) or a chemical reagent. Second, separate those pieces, almost always by the same reversed-phase HPLC used for purity work. Third, identify each piece, most rigorously by mass spectrometry, which can assign a mass to every fragment and compare it against the fragment masses the intended sequence should produce. The resulting chromatographic and mass pattern, the map, is the fingerprint checked against a reference standard or a theoretical prediction.
USP carries the same method under General Chapter <1055>, Biotechnology-Derived Articles: Peptide Mapping, a chapter developed through the Pharmacopeial Discussion Group and harmonized with the corresponding chapters in the Japanese and European Pharmacopoeias. Both the USP chapter and ICH Q6B were written primarily for recombinant proteins and other biotechnology-derived articles, the domain where peptide mapping first became a standard release test.
Why an intact mass match is not the same as a confirmed sequence
The reason this matters for anything smaller than a full protein is straightforward. ICH Q6B's identity-testing section requires that an identity test be "highly specific for the drug substance" and "based on unique aspects of its molecular structure," and it points back to methods like peptide mapping as the tools available to meet that bar. Intact-mass matching, the technique behind most peptide identity lines on a COA, is specific to gross composition, not to the order of that composition. A peptide built from the correct amino acids in the wrong internal order, or with two residues transposed, or with an isobaric substitution such as leucine for isoleucine, can present an intact mass indistinguishable from the correct sequence. None of those errors would show up as a mass mismatch, because none of them changes the total mass.
Fragment-level analysis is what catches this. A 2002 methods reference on synthetic peptide chemistry, published in Current Protocols in Protein Science (Stawikowski and Fields, PMID 18429226, full text via PMC), states it directly: "Efficient characterization of synthetic peptides has been obtained by a combination of RP-HPLC and MS, with sequencing by either Edman degradation sequence analysis or tandem MS being used to identify the positions of modifications and deletions." The operative phrase is "positions": once a peptide has been broken down and its fragments individually placed and identified, an error that intact mass hides can no longer hide, because it now shows up as a fragment with the wrong mass, or a fragment missing where one should be, or a fragment appearing where none should.
Peptide mapping for a full protein versus MS/MS for a short peptide
There is a real distinction worth being precise about. USP <1055> and ICH Q6B describe peptide mapping as applied to recombinant proteins and larger biotechnology-derived articles, molecules large enough that enzymatic digestion into a set of manageable fragments is a practical necessity before any of those fragments can be analyzed. Most research peptides sold and tested outside that context (in the 5 to 40 amino acid range typical of synthetic research peptides) are already short enough that a mass spectrometer can fragment the intact molecule directly, using collision-induced dissociation, without an upstream digestion step. That direct approach is tandem mass spectrometry, MS/MS, the same technique our mass spectrometry guide named as the way past the leucine and isoleucine problem.
The chapter and the shorter-peptide case are not the same procedure, but they rest on the identical principle: do not stop at the mass of the intact molecule, break it (whether by an enzyme beforehand or by collision inside the instrument) and check that the pieces match what the correct sequence should produce. A COA that reports only an intact observed-versus-theoretical mass match has not run this check, in either its digestion-based or its direct MS/MS form. A COA that reports MS/MS sequence coverage, or a peptide map compared against a reference standard, has gone a level deeper than mass alone.
What this does and does not mean for a COA
None of this makes an intact-mass identity result worthless. For most research use, an observed mass that matches the theoretical mass within the expected tolerance is a reasonable, widely used check, and running it is standard practice. What sequence-level analysis adds is coverage of the specific failure modes, positional errors and isobaric substitutions, that intact mass structurally cannot see. Whether a given report includes that deeper check is a question about which method was actually run and documented, not a question about the laboratory's or the supplier's transparency. A COA that redacts a client or manufacturer's name while reporting full MS/MS sequence coverage has disclosed more of the data that actually matters than one that names every party involved but stops at a single intact mass number. The verifiable content of the report, not who is willing to be named on it, is what determines how much the document actually establishes.
Further reading
The intact-mass identity check that peptide mapping and MS/MS extend beyond is covered in mass spectrometry for peptide identity verification, including the leucine and isoleucine limitation this article builds on. The chromatographic separation step that both purity testing and peptide mapping rely on is explained in HPLC for peptides.
For the standards themselves, the primary references are ICH Q6B, Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, USP General Chapter <1055>, Biotechnology-Derived Articles: Peptide Mapping, and Stawikowski and Fields, "Introduction to Peptide Synthesis," Current Protocols in Protein Science (2002), PMID 18429226, DOI 10.1002/0471140864.ps1801s26, available via PMC.